Inimmune

05/04/2026

May is , a month dedicated to helping patients and families educate their communities and advocate for safety.

Food allergies may be unseen, but they should never be unnoticed. At Inimmune, we’re advancing our allergy program with the needs of millions of people worldwide living with in mind.

04/22/2026

Our CEO, David Burkhart, Ph.D., will present at the Food Allergy Fund Summit taking place April 29, 2026, in NYC.

Dr. Burkhart will join leaders advancing new approaches to treatment and prevention to discuss translating science into solutions for patients with food allergies.

We look forward to joining these critical conversations shaping the future of research and innovation.

Check out the agenda here: https://foodallergyfund.org/summit2026

04/08/2026

What does it take to develop a disease-modifying therapy for allergic rhinitis?

In a recent interview with Leader’s Proch, our CEO Burkhart shares how Inimmune is advancing INI-2004, a novel intranasal designed to reprogram the immune system and deliver durable responses for patients.

The discussion also explores the nuances of clinical trials, from seasonal timing to the role of controlled chamber studies in improving signal detection.

Read more: https://www.clinicalleader.com/doc/considerations-for-allergic-rhinitis-trials-are-nothing-to-sneeze-at-0001

Inimmune CEO David Burkhart explains how a GSK layoff led to the formation of a new company focused on treating allergic rhinitis. Here, he shares success from the companys approach to site selection, trial design, and timing.

03/26/2026

INIMMUNE IS ON THE MOVE AT THE WVC

We’re excited to share some big updates—highlighted by a special co-presentation from our own Dr. Juhienah Khalaf alongside Dr. Peter Tygesen, Business Development Director at SPI Pharma (our valued partner):
🗓 March 30
📍 Room 209AB
🕛 12:20 PM EST
“Innovative Adjuvants for Global Health.”
Join us at WVC in Washington, DC for the presentation and visit us at booth #452 to explore our cutting-edge adjuvant system pipeline and see how we’re helping shape the future of global health. 💉🔬

03/12/2026

INIMMUNE COMPLETES ENROLLMENT AND DOSES FIRST PATIENT IN PHASE 2 CHAMBER TRIAL OF INI-2004 FOR ALLERGIC RHINITIS

INI-2004 advances as a rapid, disease-modifying immunotherapy for allergic rhinitis with platform potential across all allergic diseases; topline data expected June 2026
Missoula, MT — March 11, 2026 — Inimmune Corporation, a clinical-stage biotechnology company developing novel immunotherapies for allergic diseases, today announced the completion of enrollment and dosing of the first patient in its Phase 2 allergen challenge chamber trial evaluating INI-2004 in patients with allergic rhinitis.
“Allergic rhinitis affects hundreds of millions of people worldwide, yet treatment options remain largely limited to symptom control or lengthy allergen-specific immunotherapy programs,” said David Burkhart, Ph.D., CEO of Inimmune Corporation. “Completing enrollment and dosing the first patient in our Phase 2 study is a significant step toward demonstrating that INI-2004 can rapidly and durably modify the immune response driving allergic disease. We look forward to reporting topline data from the study in June.”
The randomized, placebo-controlled Phase 2 trial is designed to evaluate the safety, tolerability, and efficacy of INI-2004 in patients with allergic rhinitis using a validated allergen exposure chamber model. INI-2004 targets innate immune pathways that drive allergic inflammation and is designed to rapidly reprogram immune responses to allergens, potentially delivering a disease-modifying effect independent of the specific allergen trigger.
“We believe INI-2004 represents a true ‘pipeline in a product,’” said Ferdinand Massari, M.D., Chief Medical Officer of Inimmune Corporation. “By targeting core innate immune pathways involved in allergic disease, this program has the potential to extend beyond seasonal and perennial allergic rhinitis into additional indications, such as food allergies, allergic asthma, and other atopic conditions. Our goal is to deliver a disease-modifying immunotherapy that simplifies treatment for patients and clinicians while transforming how allergic diseases are managed.”
Following completion of the Phase 2 allergen chamber study, Inimmune plans to engage with regulatory authorities to determine the path forward for late-stage clinical development and potential expansion into additional allergic and asthma-related indications.
About INI-2004
INI-2004 is an investigational, allergen-agnostic immunotherapy designed to reprogram immune responses to allergens by activating toll-like receptor 4 (TLR4), a key pathway involved in innate immune signaling. By targeting core immune mechanisms underlying allergic disease, INI-2004 is being developed as a rapid, disease-modifying treatment that may be effective across multiple allergens.
Inimmune is advancing INI-2004 into clinical studies designed to further evaluate its safety and efficacy in allergic rhinitis and other allergic diseases.
About Inimmune Corporation
Inimmune is a clinical-stage biotechnology company focused on the discovery and development of next-generation immunotherapies for the treatment of infectious diseases, allergy, and cancer. Leveraging its proprietary technology platforms, Inimmune is dedicated to creating safe and effective treatments that harness the immune system to improve patient outcomes. For more information, follow us on LinkedIn and visit www.inimmune.com/.
For more information about Inimmune Corporation, contact:
Email: Info@inimmune.com
Phone: 406-541-5913

03/05/2026

Inimmune Adds Key Executives in Advance of Phase 2 Allergic Rhinitis Data to Accelerate Clinical Expansion into Food Allergy and Allergic Asthma

Missoula, MT – February 26, 2026 – Inimmune Corporation, a clinical-stage biotechnology company developing next-generation immunotherapies, today announced the appointments of Dr. Ferdinand Massari as Chief Medical Officer and Ryan McMillian as Head of Financial Strategy. The addition of these two accomplished biotech industry veterans strengthens the company’s leadership team as Inimmune advances the clinical expansion of its lead allergic rhinitis program into allergic asthma and food allergy.
Dr. Massari brings more than two decades of experience in clinical development and translational medicine across immunology and inflammatory diseases. He has a proven track record of building high performing clinical teams to deliver commercial success at both biotech and large pharma companies. As CMO, he will lead Inimmune’s clinical strategy and ex*****on, guiding the continued development of the company’s lead allergy program and its planned expansion into allergic asthma and food allergy, two areas with significant unmet patient need and limited disease-modifying treatment options. Dr. Massari is assuming the role of CMO previously held by Dr. Jon Ruckle, who successfully led Inimmune’s oncology and allergy programs through Phase 1 clinical trials.
Mr. McMillian joins Inimmune as Head of Financial Strategy, bringing extensive expertise in biotech finance, corporate strategy, and capital formation. In this role, he will oversee financial planning and strategic initiatives designed to support the company’s growing clinical portfolio and long-term value creation strategy.
“Inimmune is entering an important phase of growth as we broaden the scope and impact of our allergy program,” said David Burkhart, Chief Executive Officer of Inimmune Corporation. “Our Phase 2 trial in allergic rhinitis is completing enrollment and we expect to report top-line data in June 2026. As we prepare to expand into allergic asthma and food allergy, Dr. Massari’s deep clinical development experience and Mr. McMillian’s financial and strategic leadership will be instrumental in successfully supporting that expansion.” Dr. Massari added, “INI-2004 could revolutionize the treatment of allergic rhinitis and food allergies providing patients with the first truly disease-modifying therapy that is highly safe, effective, rapid and convenient.”
Building on this milestone, the company is preparing to expand development of their rapid, disease modifying immunotherapy to include allergic asthma and food allergy—conditions that affect millions worldwide and impose a substantial health and economic burden.
The appointments of Dr. Massari and Mr. McMillian reflect Inimmune’s commitment to assembling a world-class leadership team capable of advancing innovative immunotherapies through clinical development and toward commercialization.
About Inimmune Corporation
Inimmune is a clinical-stage biotechnology company focused on the discovery and development of next-generation immunotherapies for the treatment of infectious diseases, allergy, and cancer. Leveraging its proprietary technology platforms, Inimmune is dedicated to creating safe and effective treatments that harness the immune system to improve patient outcomes.

Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the clinical development, potential benefits, and future prospects of INI-2004. These statements are subject to risks and uncertainties that could cause actual results to differ materially. Inimmune undertakes no obligation to update any forward-looking statements.

For more information about Immune Corporation, contact:
https://inimmune.com/
Email: Info@inimmune.com

Harnessing the Immune System to Improve Human Health Our Pipeline Our Pipeline Harnessing the Immune System to Improve Human Health Our Pipeline Our Pipeline July 24, 2024 July 16, 2024 May 15, 2024 January 8, 2024 December 1, 2023 November 30, 2023 July 24, 2024 July 16, 2024 May 15, 2024 January 8...

03/03/2026

Inimmune is looking for a Formulations Research Associate. Check out the posting below.

03/03/2026

.......... .
lnimmune
Job Description

JOB TITLE: RESEARCH ASSOCIATE
Work Location: Inimmune - 1121E Broadway, Ste 121, Missoula, MT 59802
Division/Department: □ Chemistry □ Immunology � Formulations □ Admin □ Quality □ Clinical
Supervisor/Manager:
Work Status: � Full-time □ Part-time □ Contract

Duties and Responsibilities:
Contribute to the design, preparation, and characterization of novel vaccine and adjuvant formulations supporting discovery and early development programs.
Perform and support development of analytical methods, including HPLC and physicochemical characterization techniques, to evaluate formulation performance, stability, and quality attributes.
Design and execute experiments with increasing independence while collaborating cross-functionally with immunology and chemistry teams.
Ability to perform limited troubleshooting with formulation methods and analytical instrumentation.
Designs experiments with limited/some supervision.
Maintain accurate and compliant laboratory records and review notebooks of team members for quality.
Ensure compliance with all company policies, SOPs, and safety standards.
Contribute to the preparation of technical presentations and data summaries for departmental and company meetings.
Education, Skills, and Experience Requirements:
Bachelor’s degree with 2 or more years, or master’s degree with 1 or more years, of relevant laboratory experience.
Experience developing, optimizing, and executing HPLC methods for analytical characterization is desirable.
Strong hands-on laboratory skills, including accurate experimental ex*****on, solution preparation, data analysis, and meticulous documentation.
Working knowledge of FDA regulatory expectations and documentation practices related to drug development is preferred.
Strong written and verbal communication skills, with the ability to summarize and present experimental findings to cross-functional teams.
Proficiency in statistical evaluation and graphical presentation of scientific data using appropriate analytical tools.
Proficiency in Microsoft Office applications, including Excel, Word, and PowerPoint, for data analysis, documentation, and presentation preparation.
Ability to manage multiple priorities and meet project timelines in a fast-paced research environment.
Physical Requirements:
Able to perform essential duties consistent with ADA, FMLA, and other federal, state, and local standards.
Ability to maintain regular and punctual attendance consistent with ADA, FMLA, and other federal, state, and local standards.
Ability to lift 50 lbs.
Supervisory Responsibilities:
None

02/04/2026

MEDICINAL CHEMISTRY INTERN 2026
Join Inimmune Corp. as a Medicinal Chemistry Intern to gain hands-on experience synthesizing compounds and collaborating on drug discovery and development projects.
Key responsibilities include:
• Synthesizing novel chemical intermediates and final compounds.
• Reviewing chemical literature to guide reaction sequences.
• Setting up, monitoring (TLC and/or LCMS and/or HPLC) and working-up reactions.
• Purifying compounds by automated chromatography or recrystallization.
• Generating and interpreting analytical data.
• Helping develop plans to address medicinal chemistry goals.
• Maintaining a complete laboratory notebook.
• Work closely with experienced chemists to learn process and discovery programs for optimization, synthesis and characterization of small organic compounds.
The company is looking for:
• Enrollment in an undergraduate/graduate degree program in Organic Chemistry or Medicinal Chemistry.
• Practical experience with organic synthesis, methods development, total synthesis, or similar.
• Ability to work in a laboratory environment.
• Minimum of one-year prior laboratory experience.
• Good verbal and written communication skills.
• Creative thinking and teamwork abilities.
• Interest in attending program events including social gatherings and career development workshops.
• Ability to commit to a 12 week, full-time, 40 hours per week, during summer 2026.
• Legal authorization to work in the United Stated without sponsorship, now and in the future.
• Position is fully onsite at the Missoula, Montana location.
Training & Development
• Exposure to medicinal chemistry research and cross-functional collaboration
• Opportunity to learn about adjuvants discovery principles
• Gain professional hands-on experience in a Biotech company setting.
• Social events for interns and company-wide participation

Apply online via Indeed or send resume / CV directly to HR@Inimmune.com

12/05/2025

Generation of a shelf-stable, broadly-reactive influenza vaccine formulated
with TLR4, TLR7/8, or TLR9 stimulating adjuvants

12/05/2025

https://authors.elsevier.com/c/1mDZO_,cUWobFE